ClinicalTrials.gg
CompletedNCT01836861Updated Mar 17, 2021

IPI-145 ADME and Absolute Bioavailability Study

A Phase 1 interventional study of IPI-145 in Healthy, sponsored by SecuraBio. Completed at 1 site in Netherlands. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-17.

Sponsored by SecuraBio · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

This is an open-label, 2-period, absorption, distribution, metabolism and excretion (ADME) and absolute bioavailability study in 6 healthy adult male subjects.

Read the detailed description

In Period 1, subjects will receive a single oral dose of 25 mg IPI-145, followed by a 15-minute IV infusion of approximately 2.8 μg 14C-IPI-145 containing 14.8 kBq of radioactivity.

In Period 2, the same subjects will receive a single dose of 25 mg 14C-IPI-145 as an oral suspension, containing approximately 3.15 MBq of radioactivity.

There will be a washout period of at least 14 days between Period 1 and Period 2.

02

Conditions studied

  • Healthy

Keywords

  • Phase I
  • healthy male volunteers
  • ADME
  • Bioavailability
  • PI3K inhibitor
  • Absorption
  • Distribution
  • Metabolism
  • Excretion
  • safety
03

In context

Lead sponsor

SecuraBio is the lead sponsor of 25 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males, between 18 and 45 years of age, inclusive (BMI) : 18.0-30.0 kg/m2
  • In good health, determined by no findings from medical history, physical examination (Check-in), 12-lead , and vital signs
  • Provision of signed and dated, written prior to any study specific procedures

Exclusion criteria

Exclusion Criteria:

  • Evidence of medical conditions
  • History of gastrointestinal surgery that may affect drug absorption
  • Positive or indeterminate QuantiFERON-TB Gold test at screening
  • Any active infection at the time of screening or admission
  • Participation in another ADME study with a radiation burden >0.1 mSv in the period of 1 year before screening
  • Irregular defecation pattern (less than once per 2 days)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    IPI-145 and [14C] IPI-145

    Drug: IPI-145

Interventions

  • Intravenous infusion: approximately 2.8 μg IPI-145 containing 14.8 kBq of radioactivity; Oral suspension: 25 mg IPI-145 containing approximately 3.15 MBq of radioactivity; Oral capsule: 25 mg IPI-145

06

What researchers measure

Primary outcomes

  1. PK parameters (AUC) of IPI-145 in plasma

    Time frame: over 48 hours

  2. PK parameters (AUC) and radioactivity excreted in urine and feces

    Time frame: over 144 hours

  3. PK parameters (Cmax) of IPI-145 in plasma

    Time frame: over 48 hours

  4. PK parameters (t1/2) of IPI-145 in plasma

    Time frame: over 48 hours

  5. PK parameters (Cmax) and radioactivity excreted in urine and feces

    Time frame: over 144 hours

  6. PK parameters (t1/2) and radioactivity excreted in urine and feces

    Time frame: over 144 hours

Secondary outcomes

  1. Number of participants with adverse events following a single dose administration of IPI-145

    Time frame: over 4 weeks

07

Study locations

1 site
  • Pharmaceuticals Research Association (PRA)
    Zuidlaren, Netherlands
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2013, a primary completion of Apr 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2013
First posted
Apr 22, 2013
Start
Mar 2013
Primary completionActual
Apr 2013
CompletionActual
May 2013
Last update
Mar 17, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01836861
Lead sponsor
SecuraBio
Responsible party
Sponsor
First posted
Apr 22, 2013
Start date
Mar 2013
Primary completion
Apr 2013
Completion
May 2013
Last update
Mar 17, 2021

Study contacts

Hagop Youssoufian, MD
study chair · Verastem, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Duvelisib

Start the discussion